Ryan Livingston

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Articles

The trial showed a substantial decrease in the Lichen Planopilaris Activity Index, indicating reduced inflammatory disease activity. | Image credit: Nadya Kolobova - stock.adobe.com

Baricitinib Reduces Disease Activity in Postmenopausal Frontal Fibrosing Alopecia

November 21st 2025

Baricitinib demonstrated significant reductions in disease activity in postmenopausal women with frontal fibrosing alopecia over 12 weeks.

Doctor touching an AI-generated image of a heart. | Image Credit: TechTonic - stock.adobe.com

Papillary Muscle Scarring May Predict Cardiac Death in Dilated Cardiomyopathy

November 14th 2025

Papillary muscle scarring has a substantial association with both cardiovascular mortality and arrhythmia.

Among currently approved oral JAKis, deuruxolitinib 8 mg BID appeared in the analysis to provide the greatest short-term efficacy for those living with severe disease. | Image Credit: onephoto - stock.adobe.com

Deuruxolitinib Shows Greatest Short-Term Efficacy Among JAKis for Severe Alopecia Areata

October 30th 2025

Deuruxolitinib 8 mg BID was found to be the most effective oral JAK inhibitor for severe alopecia areata in a new meta-analysis.

PAH | Image Credit: Maggie-sora.chatgpt.com

FDA Reviewing Sotatercept-csrk Label Expansion for PAH

July 14th 2025

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777